Avalo Therapeutics On Sept 12, Got Notice From Nasdaq As Of Sept 11 Co's Securities Had Closing Bid Price Of $0.10/less For 10 Consecutive Trading Days
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics received a notice from Nasdaq on September 12, stating that the company's securities had a closing bid price of $0.10 or less for 10 consecutive trading days.
September 13, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avalo Therapeutics' stock price has been consistently low, which may lead to potential delisting from Nasdaq if the situation persists.
Avalo Therapeutics' stock price has been consistently low, which is a violation of Nasdaq's listing rules. If the company fails to raise its stock price above the minimum bid price requirement within the grace period, it may face delisting from the exchange. This could negatively impact the company's reputation and investor confidence, leading to a potential decrease in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100